On Monday, in the course of current trade, Shares of Viacom, Inc. (NASDAQ:VIAB), climbed 1.89%, and is now trading at $46.31.
Viacom Inc., stated financial results for the quarter ended June 30, 2015, counting a 4% enhance in adjusted diluted earnings per share to $1.47, a record high for the June quarter.
Sumner M. Redstone, Executive Chairman of Viacom, said, “Viacom is meeting the challenges of a rapidly-changing media landscape by creating exciting, unique content that connects with audiences on all platforms. Our administration team is positioning Viacom for success, and I am confident that we have the strategies in place to thrive.”
Viacom Inc. operates as an entertainment content company in the United States and internationally. The company creates television programs, motion pictures, short-form video, applications, games, consumer products, social media, and other entertainment content. It operates in two segments, Media Networks and Filmed Entertainment.
During an Afternoon trade, Shares of Envision Healthcare Holdings Inc (NYSE:EVHC), climbed 0.59% , and is now trading at $44.34.
Envision Healthcare Holdings, stated results from operations for the three months and six months ended June 30, 2015. All comparisons comprised of in this release are for the 2015 periods to the comparable 2014 period, unless otherwise noted.
Highlights:
- Net revenue raised by 25.9% to $1.35 billion;
- Adjusted EBITDA grew by 20.5% to $162.8 million;
- Net income was $52.4 million, contrast to a net loss of $2.0 million;
- Adjusted EPS was $0.37, an enhance of 32%, and GAAP diluted EPS was $0.27 for the quarter; and
- Envision, through its AMR partner, has reached a definitive agreement to acquire the medical transportation company Rural/Metro Corporation, with estimated annual revenue for 2015 of $600 million, further advancing Envision’s mobile integrated healthcare delivery strategy.
“We continue to deliver strong financial results while at the same time expanding our clinical capabilities and aligning our resources to care for patients across a variety of healthcare settings,” said William A. Sanger, chairman, president and chief executive officer. “Our top-line growth for the second quarter reflects strong organic growth and contributions from regional provider groups that joined our organization through acquisition.
Envision Healthcare Holdings, Inc. provides physician-led, outsourced medical services to consumers, hospitals, healthcare systems, health plans, and government entities in the United States.
Finally, ABIOMED, Inc. (NASDAQ:ABMD), gained 1.38% Monday.
Abiomed, stated first quarter fiscal 2016 revenue of $73.4 million, an enhance of 50% contrast to revenue of $48.8 million for the same period of fiscal 2015. First quarter fiscal 2016 GAAP net income was $8.9 million or $0.20 per diluted share, contrast to GAAP net loss of $1.7 million or a loss of $0.04 per diluted share for the preceding year period.
Financial and operating highlights during the first quarter of fiscal 2016 comprise:
- Fiscal first quarter worldwide Impella revenue totaled $68.8 million, an enhance of 53% contrast to revenue of $45.0 million during the same period of the preceding fiscal year. U.S. Impella revenue grew 60% to $63.7 million from $39.9 million in the preceding fiscal year with U.S. Impella patient usage up 62%.
- An additional 15 hospitals made initial purchases of Impella during the quarter, contrast to 24 new hospital sites in the preceding year period, bringing the installed customer base to 973 sites. As part of Abiomed’s continued Impella CP launch, 54 new hospitals purchased Impella CP, bringing the total number of Impella CP U.S. sites to 694.
- An additional 15 sites made initial purchases of the Impella RP during the quarter, bringing the total number of Impella RP U.S. sites to 23.
- Gross margin for fiscal first quarter 2016 was 85% contrast to 80% in the first quarter of fiscal 2015. Margins were boosted by favorable product mix and Euro exchange rates in addition to raised factory utilization.
- Fiscal first quarter income from operations was $15.0 million, or operating margin of 20% contrast to a loss from operations of $1.5 million in the preceding year period.
- Cash, cash equivalents, short and long-term marketable securities totaled $156.4 million as of June 30, 2015, contrast to $146.0 million at March 31, 2015. The Company continues to have no debt.
- In June, Abiomed declared that it received confirmation from the United States Department of Justice that it has closed its investigation into the company’s marketing of the Impella 2.5 device without pursuing any enforcement action.
- On July 15, Abiomed hired Michael Tomsicek as the new Chief Financial Officer and Vice President. Former Abiomed CFO, Robert Bowen, stepped down on July 31.
- On July 31, Centers for Medicare and Medicaid Services (CMS) reconfirmed Impella reimbursement and payment. This marks more than eight years of review and validation of appropriate payment and confirms that existing Impella MS-DRG mapping (215-221) will remain unchanged in the ICD-9 to ICD-10 transition on October 1, 2015.
ABIOMED, Inc. researches, develops, and sells medical devices in circulatory support and continuum of care in heart recovery to acute heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
